{"id":"esomeprazole-sodium-for-injection","safety":{"commonSideEffects":[{"rate":"7.1","effect":"Headache"},{"rate":"5.6","effect":"Diarrhea"},{"rate":"4.8","effect":"Nausea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Esomeprazole sodium is a proton pump inhibitor that reduces gastric acid secretion by inhibiting the H+/K+ ATPase enzyme in the gastric parietal cells.","oneSentence":"Inhibits the H+/K+ ATPase enzyme","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:52:00.422Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Gastroesophageal reflux disease"},{"name":"Erosive esophagitis"},{"name":"Zollinger-Ellison syndrome"}]},"trialDetails":[{"nctId":"NCT07312370","phase":"PHASE4","title":"Esomeprazole Plus Sucralfate for Post-ESD Ulcer Healing","status":"NOT_YET_RECRUITING","sponsor":"LanZhou University","startDate":"2026-04-20","conditions":"Early Gastric Cancer, Gastric Dysplasia, Gastric Neoplasms","enrollment":120},{"nctId":"NCT06783257","phase":"PHASE2","title":"Phase II Clinical Study of Vonorasan Fumarate Injection in the Treatment of Peptic Ulcer Bleeding","status":"NOT_YET_RECRUITING","sponsor":"Shandong New Time Pharmaceutical Co., LTD","startDate":"2025-02","conditions":"Peptic Ulcer Bleeding","enrollment":150},{"nctId":"NCT06561542","phase":"PHASE1","title":"A Phase I Study of LX22001 for Injection in Healthy Subjects","status":"RECRUITING","sponsor":"Shandong Luoxin Pharmaceutical Group Stock Co., Ltd.","startDate":"2024-08-05","conditions":"Healthy","enrollment":70},{"nctId":"NCT05841394","phase":"PHASE3","title":"A Multi-center, Double-blinding, Parallel and Positive-controlled Phase III Clinical Trial for Efficacy and Safety Evaluation of Ilaprazole Sodium for Injection on Prevention of Stress Ulcer Bleeding","status":"COMPLETED","sponsor":"Livzon Pharmaceutical Group Inc.","startDate":"2021-07-16","conditions":"Stress Ulcer Bleeding","enrollment":449},{"nctId":"NCT02479581","phase":"PHASE2","title":"The Safety and Efficacy of the Enhanced Recovery After Surgery(ERAS)Applied on Cardiac Surgery With Cardiopulmonary Bypass","status":"COMPLETED","sponsor":"Xiangya Hospital of Central South University","startDate":"2015-07","conditions":"Valvular Heart Disease","enrollment":226}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"Esomeprazole sodium for injection","genericName":"Esomeprazole sodium for injection","companyName":"Shandong New Time Pharmaceutical Co., LTD","companyId":"shandong-new-time-pharmaceutical-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Inhibits the H+/K+ ATPase enzyme Used for Gastroesophageal reflux disease, Erosive esophagitis, Zollinger-Ellison syndrome.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}